Immune-Onc Therapeutics gets FDA orphan drug status for IO-202 in CMML

Immune-Onc Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies in immunology and oncology, has achieved a significant milestone with the ... Read More